Data from a Novel Patient-Reported Outcome Tool Assessing Acromegaly Treatment Satisfaction to be Presented
Tools for Patients Added to Acromegaly.care
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced an upcoming presentation of a Patient Reported Outcome (PRO) tool for acromegaly at The 8th International Congress of the GRS & IGF Society in Tel Aviv, Israel. Additionally, the company reaffirmed its support for Acromegaly Awareness Day and announced that new resources for patients and their caregivers have been added to their disease awareness website, Acromegaly.care.
Dr. Murray Gordon MD, FACE, Director of the Allegheny Neuroendocrinology Center at Allegheny General Hospital in Pittsburgh, Pennsylvania, will present new data at The 8th International Congress of the GRS & IGF Society in Tel Aviv, Israel on the ACRO-TSQ, a novel acromegaly-specific Patient Reported Outcome (PRO) tool assessing treatment satisfaction and burdens related to the route of medication administration. The ACRO-TSQ is utilized in Chiasma’s ongoing Phase 3 MPOWERED™ trial, which is being conducted in the U.S., EU and other countries and is intended to support a potential submission of an application for marketing approval in the EU. More information can be found at clinicaltrials.gov. The presentation is scheduled to take place on Tuesday, November 8, 2016 at 12:15 p.m. Israel time.
“This PRO tool was developed as a means of enhancing the understanding of the acromegaly patient experience, including the burden of and satisfaction with different routes of drug administration such as injection vs. oral treatment options, symptoms and unmet needs,” said Dr. Gordon.
Also, the company announced that new content for patients, including information regarding how to partner more effectively with physicians to optimize their treatment care plans, has been added to Acromegaly.care. Created with input from a diverse group of acromegaly patients and advocates, Acromegaly.care is an educational website launched in 2015 that sheds light on the challenges and triumphs of those living with acromegaly. To find out more, click here.
“Chiasma’s long-standing partnership with the patient community has fortified our efforts in helping patients with acromegaly beyond our clinical work,” said Mark Fitzpatrick, president and chief executive officer of Chiasma. “In recognition of Acromegaly Awareness Day, we are proud to present additional resources for patients and their loved ones dealing with this rare and debilitating disease. We also continue to participate in the dialogue with endocrinologists about new ways to assess patients’ experience with today’s acromegaly treatments.”
Acromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone (GH), ultimately leading to significant health problems and early death if untreated. There are an estimated 69,000 individuals with acromegaly worldwide. In 13 studies of acromegaly prevalence since 1980, an average of approximately 75 cases per million was determined, suggesting roughly 24,000 individuals with acromegaly in the United States, of which an estimated 8,000 are treated chronically with somatostatin analog injections. Because symptoms often develop slowly, diagnosis may be delayed by years or decades, making it difficult to determine the total number of people with the disease.
Chiasma is dedicated to improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. The company is headquartered in the United States with a wholly-owned subsidiary in Israel. Chiasma, the Chiasma logo, and MPOWERED are trademarks of Chiasma.
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s ability to help patients with acromegaly. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with the regulatory review and approval process generally and risks associated with Chiasma’s Phase 3 clinical trial to support regulatory approval of Mycapssa in the E.U. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Chiasma’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission (SEC) on March 17, 2016, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 filed with SEC on August 11, 2016 and in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Chiasma undertakes no duty to update this information unless required by law.
Contact: Cammy Duong MacDougall Biomedical Communications (781) 591-3443 firstname.lastname@example.org